Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05855200RecruitingPhase 3
Dostarlimab around surgery for certain untreated colon cancers
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
Tucson, ArizonaAges 18 years+ - NCT05861986RecruitingPhase 4
Risdiplam for very young children after gene therapy for SMA
This trial studies whether risdiplam, given early after gene therapy, is safe and helps children with spinal muscular atrophy (SMA) keep improving or stay stable. It focuses on children under 2 years old who already received gene therapy and need to meet timing and health requirements.
Little Rock, ArkansasAges 3 months–2 years - NCT05871970RecruitingPhase 2
TARA-002 treatment for lymphatic cysts in children
This Phase 2 trial tests whether an injected medicine called TARA-002 placed inside lymphatic cysts can safely shrink lymphatic malformations in children. It may help especially when the cysts are mainly in the head, neck, or chest area.
Birmingham, AlabamaAges 6 months–18 years - NCT05876312RecruitingPhase 1/Phase 2
Study drug ADX-038 in healthy people and PNH patients
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
Brisbane, QueenslandAges 18 years+ - NCT05878769RecruitingPhase 3
Long-term safety study for Astegolimab in COPD
This study looks at how safe Astegolimab stays over the long run for people with COPD. It enrolls participants who finished a prior 52-week Astegolimab treatment study and may help confirm long-term side effects and overall safety.
Birmingham, AlabamaAges 40–90 - NCT05884983Recruiting
Check if special CT and nose scope help screen nasopharyngeal cancer
This study tests whether combining a special CT scan with a nose/throat camera exam (nasopharyngeal endoscopy) can better find nasopharyngeal cancer early. You might benefit if the study shows this approach is accurate and safer for screening.
Zhongshan, GuangdongAges 30–69 - NCT05889182RecruitingPhase 3
Testing an oral medicine for moderate to severe hidradenitis
This Phase 3 study tests upadacitinib taken by mouth to reduce hidradenitis suppurativa (HS) symptoms and disease activity, and to track side effects. It is for people who have already tried anti-TNF treatments and still had inadequate response or couldn’t tolerate them.
Birmingham, AlabamaAges 12 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Gilbert, ArizonaAges 18 years+ - NCT05902559Recruiting
Study of new lung-check biomarkers in older adults
This study looks at new blood or test “biomarkers” to understand how well targeted lung health checks work. You join if you’re already attending the NHS lung health check program and can consent.
LondonAges 55–74 - NCT05916287Recruiting
STANISLAS cohort follow-up visit for heart and kidney health
This study is a follow-up visit for people who joined the STANISLAS family health cohort. Researchers look at how genes and environment may affect heart and kidney (kidneys) health over time.
Vandœuvre-lès-Nancy, LorraineAges Any age - NCT05918523Recruiting
Long-term follow-up for people treated with REACT
This study checks long-term health outcomes in people who previously received a treatment called REACT for chronic kidney disease. It may help doctors understand how safe and effective REACT is over time.
Meridian, IdahoAges 30–80 - NCT05919030RecruitingPhase 3
Tislelizumab with chemoradiation for advanced esophagus cancer
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Wuhan, HubeiAges 18 years+ - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT05927571RecruitingPhase 1
Cevostamab and elranatamab combination study for relapsed myeloma
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
Camperdown, New South WalesAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT05935215RecruitingPhase 3
Switch from anti-C5 shots to iptacopan for aHUS
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
Nanjing, JiangsuAges 18–100 - NCT05940272Recruiting
Communication training for doctors treating large B-cell lymphoma
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
New York, New YorkAges 18 years+ - NCT05942066Recruiting
Study to standardize blood handling for liquid biopsy
This study checks the best, most consistent way to process whole blood so “liquid biopsy” testing results are reliable. You may help by providing blood samples, as long as you meet the health and consent requirements.
MilanAges 18 years+ - NCT05943249Recruiting
MRI technique study using healthy adult volunteers
This is a study that tests new ways to use MRI (a body scan that uses magnets) using healthy volunteers. It helps researchers improve scanning methods, which may make future scans safer or clearer.
LondonAges 18 years+ - NCT05944237RecruitingPhase 1/Phase 2
Early trial for advanced cancers using HTL0039732
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
CambridgeAges 18 years+ - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT05968326RecruitingPhase 2
Chemo plus new vaccines versus chemo alone after pancreatic surgery
This Phase 2 trial tests whether adding two study medicines (an immune-based vaccine treatment plus atezolizumab) to standard chemo helps prevent pancreatic cancer from coming back after surgery. It compares the combination against standard chemo alone, looking at safety and how well it prevents relapse.
Los Angeles, CaliforniaAges 18 years+ - NCT05978128Recruiting
Use advocates to boost lung cancer screening
This trial tests whether trained advocates and supporters can help people who are eligible for lung cancer screening actually get screened. It may help you (and others) by making screening easier to plan and complete.
Los Angeles, CaliforniaAges 40–80
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.